Literature DB >> 34822053

Clinical profile and microbiological trends of therapeutic keratoplasty at a network of tertiary care ophthalmology centers in India.

Anthony Vipin Das1, Sunita Chaurasia2, Joveeta Joseph3, Aravind Roy4, Sujata Das5, Merle Fernandes6.   

Abstract

OBJECTIVE: To describe the clinical profile and microbiology trends in patients undergoing therapeutic keratoplasty at a multi-tier ophthalmology hospital network in India.
METHODS: This cross-sectional hospital-based study included 3147 eyes undergoing therapeutic keratoplasty between Jan 2016 and Dec 2020 (5 years period) as cases. The demographic data, clinical profile and microbiological analysis were collected using an electronic medical record system.
RESULTS: Of a total of 13,625 eyes with microbial keratitis(non-viral), 3147 (23.1%) underwent therapeutic keratoplasty during the study duration. Majority of patients were males (68.35%), from a rural geography (49.89%) and in 51-60 years age bracket (23.74%). The mean age of the patients was 50.54 ± 15.83 years. Two-thirds of patients were from lower socio-economic strata (66.63%) with an agrarian background (36.51%). Of the 3,147 eyes, fungus (51.8%) was the most common indication of therapeutic keratoplasty followed by bacteria (16.87%) and parasite (1.27%). No organisms could be identified in about a third (29.33%) of the cases. Between 2016 and 2020, the trend of therapeutic keratoplasties for fungal infections steadily grew (39.9% vs 45.49%) while the bacterial infections showed a steady decline (23.15% vs 11.81%).
CONCLUSIONS: Medical cure rate was seen in majority of those with microbial keratitis, and 23.1% eventually required management with therapeutic keratoplasty. Fungal keratitis was the most common indication for therapeutic keratoplasty. Male gender, rural setting, low socio-economic background and agricultural occupation are common risk factors for patients undergoing therapeutic keratoplasty in India.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Electronic medical records; India; Keratitis; Keratoplasty; Therapeutic keratoplasty

Mesh:

Year:  2021        PMID: 34822053      PMCID: PMC8613725          DOI: 10.1007/s10792-021-02127-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.029


Introduction

Microbial keratitis substantially contributes to global blindness and is estimated to be the fourth leading cause of blindness worldwide [1]. Medical treatment is the first line of management and can be effective in achieving a clinical cure when specific treatment is instituted at an early stage of the disease. Those with advanced disease and refractory to the medical treatment are managed by performing therapeutic keratoplasty. The primary aim of the surgery is to eliminate the infective foci and restore globe integrity [2]. The procedure involves a meticulous surgery, intensive post-operative management care and close follow up for complications particularly recurrence of infection in cases due to fungus and parasitic infection. There is a distinct geographic variation in the burden of microbial keratitis. The countries with developed health care system report lower number of cases requiring therapeutic keratoplasty [3-5] compared to the ones with a developing health care system, where it contributes to a significant percentage of all keratoplasties [6-8]. Severity of the infection, delayed presentation and empirical treatment due to lack of microbiological confirmation have all been shown to contribute to poor outcomes in patients with microbial keratitis [5–7, 9]. Knowledge about the evolving trends in the microbiological spectrum of the causative organisms is crucial to help better manage care in these patients. The initial pre-operative microbiological work up from the corneal scraping samples, the cultures and histology of the host corneal button excised during therapeutic keratoplasty provide invaluable information that guide the medical therapy in the post-operative period, to eliminate the infection and achieve a clinical cure [10]. There is a paucity of large series on the clinical profile and microbiological trends of therapeutic keratoplasty in the Indian population. The aim of the authors in this study is to present the clinical profile and the microbiological trends of patients undergoing therapeutic keratoplasty at a large multi-tier ophthalmology network in India using electronic medical record driven analytics.

Materials and methods

Study design, period, location and approval

This cross-sectional observational hospital-based study included all patients undergoing therapeutic keratoplasty between January 2016 and December 2020 to the tertiary centers of an ophthalmology network spread across 4 adjacent neighboring states (Telangana, Andhra Pradesh, Odisha and Karnataka) of India [11]. A standard consent form for electronic data privacy was filled by the patient or the parents or guardians of the patient at the time of registration. None of the data that were used for analysis had identifiable parameters of the patient. The study adhered to the Declaration of HELSINKI and was approved by the Institutional Ethics Committee, Hyderabad, India. The clinical data of each patient who underwent a comprehensive ophthalmic examination using a standardized template were entered into a browser-based electronic medical records system (eyeSmart EMR) by uniformly trained ophthalmic personnel and supervised by an ophthalmologist [12]. The standard protocol of management of microbial keratitis across the network is described in a previous study from the institute [7]. In brief, all eyes diagnosed to have keratitis on their first visit to the clinic, irrespective of their past diagnosis and treatment, undergo a routine microbiological evaluation that involves smear and culture examination of samples obtained on corneal scrapings. If the keratitis deteriorates (defined as increase in size of the infiltrate and exudates in the anterior chamber and/ or large perforation), therapeutic keratoplasty is planned on an emergency basis utilizing donor corneas provided by the network of eye banks affiliated to the institute [13, 14]. At the time of therapeutic keratoplasty (whenever possible), the infected corneal button is divided into two parts. One half of the button is sent for microbiological evaluation where it is further cut and inoculated onto culture media such as blood agar, sabouraud’s dextrose agar, brain heart infusion and non-nutrient agar. The second half is sent in formalin 1% for routine histopathological analysis.

Cases

A total of 3147 eyes of patients of all ages underwent therapeutic keratoplasty at the four tertiary centers of the network during the study period. The eyeSmart EMR was initially screened for patients with: (i) completed operation coded as therapeutic keratoplasty (ii) and final microbiological diagnosis of microbial keratitis (non-viral) entered in the EMR. A total of 3,147 eyes were identified as cases, and the demographic data, clinical profile and microbiological analysis were extracted from the eyeSmart EMR database system.

Data retrieval and processing

The data of 3147 eyes included in this study were retrieved from the electronic medical record database and segregated in a single excel sheet. The columns included details such demographics, clinical presentation, surgical notes and confirmed microbiological diagnosis. The data from the excel sheet were extracted and used for analysis using the appropriate statistical software. Standardized definitions were used for occupation, socio-economic status and geographic categorization [15]. The visual acuity was classified according to the WHO guidelines [16].

Statistical analysis

Descriptive statistics using mean ± standard deviation and median with Inter-quartile range (IQR) were used to elucidate the demographic and microbiological data. Microsoft Excel (Microsoft Corporation. 2018. Redmond, USA) was used for statistical analysis and graphs.

Results

Microbial keratitis trends

A total of 13,625 cases of Microbial (Non -Viral) Keratitis were diagnosed during the 5-year study period across the tertiary centers of the eye care network. Those with the diagnosis of herpes simplex virus (HSV) keratitis were excluded. There were 5954 (43.7%) cases with fungal etiology, 3194 (23.44%) cases were bacterial, 521 (3.82%) cases with mixed infections, 213 (1.56%) cases were parasitic, 3134 (23%) cases yielded no organism on microbiological work up, and the information was not available (those with the diagnosis of microbial keratitis, but absence of tissue sample either corneal scrapings or corneal tissue in the microbiology and pathology laboratory) in 609 (4.47%) cases (Table 1). The yearly trends of the microbial keratitis are presented in Fig. 1. Overall, 3,147 patients underwent therapeutic keratoplasty accounting for 23.1% of the microbial keratitis cases diagnosed in the same period.
Table 1

Table showing the number of eyes diagnosed with microbial keratitis, with clinical diagnosis and number of eyes requiring therapeutic keratoplasty (Th PK)

ParametersOverallFungalBacterialParasiticNo organisms on microbiological workupNot available(samples not available for analysis)
No of eyes with microbial keratitis13,625595431942133134609
No of eyes that underwent Th PK314716305314092323
% of eyes that needed Th PK23.127.3816.6218.7829.453.78
Fig. 1

Trends of etiological organism in Microbial Keratitis (2016–2020)

Table showing the number of eyes diagnosed with microbial keratitis, with clinical diagnosis and number of eyes requiring therapeutic keratoplasty (Th PK) Trends of etiological organism in Microbial Keratitis (2016–2020)

Microbiological analysis and therapeutic keratoplasty trends

(Table 1) In the microbiological analysis of the corneal button of 3147 eyes that underwent therapeutic keratoplasty, fungus was identified in 1630 (51.8%) eyes, bacteria in 531 (16.87%) eyes, parasite (either Acanthamoeba/ Microsporidia) in 40 (1.27%) eyes and no growth in 923 (29.33%) eyes. Mixed infections were seen in 305 (9.69%) patients, and there was no information available in a minority of 23 (0.73%) patients. Over 2016–2020, the trends of the bacterial keratitis showed a steady decline (23.15% vs. 11.81%), while the trends of fungal keratitis showed a steady increase (39.9% vs. 45.49%). The trends of keratitis with no growth on microbiology workup also grew steadily from 24.63% vs. 35.24%. The annual distribution of the microbiological profile is detailed in Fig. 2.
Fig. 2

Microbiological trends in therapeutic keratoplasty (2016–2020)

Fungal overview: In the eyes documented with fungal growth, Fusarium species was identified in 573 (35.15%) eyes, Aspergillus species in 564 (34.6%) eyes, Pythium insidiosum in 104 (6.38%) eyes, other hyaline fungus in 98 (6.01%) eyes, dematiaceous fungus in 96 (5.89%) eyes, Candida species in 22 (1.35%) eyes and miscellaneous species were identified in 173 (10.61%) eyes. Bacterial and parasitic overview: In the eyes documented with bacterial growth that included mixed infections, gram-positive cocci were identified in 453 (54.19%) eyes, gram negative bacilli in 291 (34.81%) eyes and gram-positive bacilli in 92 (11%) eyes. Among the eyes documented with parasitic growth, Acanthamoeba was responsible for the 37 (1.27%) and microsporidia in 3 eyes. Microbiological trends in therapeutic keratoplasty (2016–2020)

Age

The mean age of the patients who underwent therapeutic keratoplasty was 50.54 ± 15.83 years while the median age was 51 (IQR: 40–62) years. The overall distribution was 2.76% (87/3,147) in children (≤ 16 years) and 97.24% (3,060/3,147) in adults (above 16 years). The frequency distribution of therapeutic keratoplasty showed an increase between 31 and 40 years of age (15.25%) and peaked between 51 and 60 years of age (23.74%) followed by gradual decline from 61 to 70 years of age (20.21%) in the subsequent decades thereafter. The decade wise distribution of the patients is detailed in Fig. 3
Fig. 3

Decade wise distribution of patients who underwent therapeutic keratoplasty (2016–2020)

Decade wise distribution of patients who underwent therapeutic keratoplasty (2016–2020)

Sex

There were 2151 (68.35%) male and 996 (31.65%) female patients who underwent therapeutic keratoplasty. Among the patients, the mean and median age were 51.37 ± 15.67 and 53 (IQR: 41 to 63) years for men and 48.76 ± 16.01 and 50 (IQR: 38 to 61) years for women, respectively. The overall mode was 56 years; 56 years for men and 51 years for women.

Rural–urban-metropolitan distribution

There were 1570 (49.89%) patients undergoing therapeutic keratoplasty from rural districts, 1483 (47.12%) from urban districts and 94 (2.99%) from metropolitan regions.

Socio-economic status

There were 2097 (66.63%) patients undergoing therapeutic keratoplasty from the lower socio-economic class, 984 (31.27%) from the lower middle class, 54 (1.72%) from the upper middle class and 12 (0.38%) from the upper class. The overall frequency distribution was significantly higher (p < 0.00001) in the lower socio-economic class as compared to the other classes.

Occupation

Of the 3147 patients who underwent therapeutic keratoplasty, 1149 (36.51%) were agriculture related; 556 (17.67%) were homemakers; 534 (16.97%) were professionals; 499 (15.86%) were manual laborers; 262 (8.33%) were currently not employed (retired or unemployed); 108 (3.43%) were students; and in the remaining 39 (1.24%) the occupational category was not available/applicable.

Laterality and year of surgery

The left eye was operated in 1611 (51.19%) cases and the right eye in 1536 (48.81%) cases. An average of 629 therapeutic keratoplasties were performed each year during 2016–2020 with the highest of 662 (21.04%) in the year 2017 to the lowest of 576 (18.3%) in the year 2020. The year wise distribution of the patients is detailed in Fig. 4.
Fig. 4

Year wise distribution of therapeutic keratoplasty (2016–2020)

Year wise distribution of therapeutic keratoplasty (2016–2020)

Risk factors

The concomitant risk factors documented at the time of first visit were diabetes in 226(7.18%), chronic alcoholism in 118(3.75%), smoking in 97(3.08%), history of contact lens usage in 10(0.32%), HIV infection in 2(0.06%) and prior usage of steroids in 46(1.46%) patients.

Presenting visual acuity

In the 3147 patients undergoing therapeutic keratoplasty, mild or no visual impairment (20/20 to 20/70) was seen in 5 (0.16%) patients, moderate visual impairment (> 20/70 to 20/200) in 14 (0.44%) patients, severe visual impairment (> 20/200 to 20/400) in 8 (0.25%) patients, blindness 3 (> 20/400 to 20/1200) in 1,307 (41.53%) patients, blindness 4 (> 20/1200 to Perception of light) in 1,399 (44.46%) patients and blindness 5 (No perception of light) in 9 (0.29%) patients. The visual acuity was undetermined or unspecified in 405 (12.87%) patients. The 9 patients who had no light perception underwent keratoplasty for tectonic reasons.

Discussion

This study sought to describe the clinical profile and the microbiological trends of patients undergoing therapeutic keratoplasty at a large multi-tier ophthalmology network in India using electronic medical record driven analytics. An important aspect of the study was to determine the trend of the microbial infection between 2016 and 2020 (5 years period) that eventually necessitates therapeutic keratoplasty. An understanding of microbiological trend over the years helps to understand the changing profile of the causative organisms of microbial keratitis requiring therapeutic keratoplasty. The subset of patients with microbial keratitis that need therapeutic keratoplasty range from 3.3 to 38% in different studies that vary in sample size, geographical locations and microbiological spectrum [17]. The Asia Cornea Society Infectious Keratitis Study [18], that included one of our centers, reported 9.47% (628/6626) eyes that were managed by therapeutic keratoplasty. Based on EMR analytics, in the present study we screened the largest number of patients with microbial keratitis that were treated across the network of tertiary care centers. Majority of microbial keratitis patients received medical treatment alone, and surgical intervention via therapeutic keratoplasty was required in 23.1% of the patients with keratitis. Although several factors determine the medical cure rate in microbial keratitis using anti-biotic therapy alone, the observation that less than one-quarter patients were managed via therapeutic keratoplasty indirectly suggests a good medical cure rate with the available anti-biotic modalities of treatment. The Asia Cornea Society Infectious Keratitis Study published in 2018, included data from 8 countries (India, China, Japan, South Korea, Taiwan, Thailand, the Philippines and Singapore) and reported country specific differences.18 Bacterial keratitis was the most common diagnosis in South Korea (42.8%) and Singapore (41.3%). Fungal species were by far the most common microorganisms isolated in China and India, with Fusarium species being the most common pathogen in China (30.9%) and India (25.7%). In the remaining countries, the most common microorganism isolated were typically bacterial, such as Pseudomonas aeruginosa in the Philippines (12.5%), Taiwan (31.9%), Thailand (32.1%) and Singapore (42.2%), and Propionibacterium acnes in Japan (33.0%) and South Korea (10.8%). In this study, fungal keratitis (5964/ 13,625; 43.7%) was the commonest cause of microbial keratitis, followed by bacterial (31,194/13625; 23.44%) and parasitic (213/13625; 1.56%) keratitis. In our cohort of patients, over 2016–2020, the trend of fungal infections steadily grew (39.9% vs 45.49%) while the bacterial infections showed a steady decline (23.15% vs. 11.81%). A study from Taiwan by Fung-Rong Hu et al. described their experience of 107 therapeutic keratoplasties and the microbiological diagnosis [8]. They reported bacteria to be the most common cause with gram negative organisms accounting for the majority (51.6%) of the cases followed by gram-positive organisms (41.9%) for the rest of the cases. In this study, the most common indication for therapeutic keratoplasty was fungal keratitis (51.8%) in over half of the cases followed by bacteria (16.87%). The most common fungal species identified were Fusarium (35.15%) and Aspergillus (34.6%) each accounting for a third of the fungal cases. Among bacterial causes of therapeutic keratoplasty, we found gram-positive cocci accounted for the majority (54.19%) followed by gram negative bacilli (34.81%) and gram-positive bacilli (11%). We also noted an increasing trend of culture negative microbial keratitis requiring therapeutic keratoplasty (24.63% in 2016 vs. 35.24% in 2020). The culture negative results are best explained by either a combination of medications started empirically prior to presentation to a tertiary eye care center, prolonged and varied therapy with delayed presentation and inadequate number of organisms for culture from the sample taken. Additionally, those eyes with near total corneal melt/perforation may have had little yield for microbiological culture studies and may have had the final diagnosis of microbial keratitis based on either clinical impression or smear examination. The increase in this trend is likely related to COVID-19 situation in the year 2020 [14]. As both the clinical and paraclinical services (Microbiology laboratory) had to work with reduced work force and there were travel restrictions, it is possible that only limited number of samples were received and tested in the microbiology laboratory services at individual centers. In this cohort, the most common systemic risk factor identified was diabetes mellitus. A history of contact lens usage was noted in a small percentage (< 0.32%). Males accounted for a higher percentage (68.35%) and the agrarian occupation which is common in India accounted for a third of the patients (36.51%) who underwent therapeutic keratoplasty in our cohort. There is a need to design and implement knowledge, awareness and prevention programs to address this vulnerable group susceptible to microbial keratitis that subsequently adds to the burden of therapeutic keratoplasty. The greatest strengths of the study include the large sample size of the cohort and a complete electronic medical record entry of the parameters that enabled efficient documentation and analysis. The eye care network is also equipped with an experienced microbiology service and clinical protocols that document corneal scraping for every suspected microbial keratitis and corneal button culture and identification of the organism post therapeutic keratoplasty. This represents real world data on a large series of microbial keratitis requiring therapeutic keratoplasty. The limitations of the study, however include its retrospective nature and the maximum medical therapy threshold at which surgical intervention would have been planned in the patients. In conclusion, this analysis of a vast number of therapeutic keratoplasties performed in a multi-tier ophthalmology network revealed that fungal keratitis as the main indication was on the rise particularly in males with an agrarian background hailing from rural areas and resulted in blindness in almost half the cohort. Hence, there is an unmet need for community programs targeting these vulnerable groups to prevent this sight threatening infection, reduce the need for therapeutic keratoplasty and its associated visual morbidity.
  17 in total

1.  Therapeutic keratoplasty.

Authors:  M FINE
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1960 Nov-Dec

2.  Thirty years of eye bank experience at a single centre in India.

Authors:  Sunita Chaurasia; Ashik Mohamed; Prashant Garg; Dorairajan Balasubramanian; Gullapalli Nageswara Rao
Journal:  Int Ophthalmol       Date:  2019-08-22       Impact factor: 2.031

3.  The Asia Cornea Society Infectious Keratitis Study: A Prospective Multicenter Study of Infectious Keratitis in Asia.

Authors:  Wei-Boon Khor; Venkatesh N Prajna; Prashant Garg; Jodhbir S Mehta; Lixin Xie; Zuguo Liu; Ma Dominga B Padilla; Choun-Ki Joo; Yoshitsugu Inoue; Panida Goseyarakwong; Fung-Rong Hu; Kohji Nishida; Shigeru Kinoshita; Vilavun Puangsricharern; Ai-Ling Tan; Roger Beuerman; Alvin Young; Namrata Sharma; Benjamin Haaland; Francis S Mah; Elmer Y Tu; Fiona J Stapleton; Richard L Abbott; Donald Tiang-Hwee Tan
Journal:  Am J Ophthalmol       Date:  2018-08-09       Impact factor: 5.258

4.  Outcomes of therapeutic penetrating keratoplasty from a tertiary eye care centre in northern India.

Authors:  Namrata Sharma; Mohit Jain; Sri V Sehra; Prafulla Maharana; Tushar Agarwal; Gita Satpathy; Rasik B Vajpayee
Journal:  Cornea       Date:  2014-02       Impact factor: 2.651

5.  Incidence and clinical characteristics of fungal keratitis in a Danish population from 2000 to 2013.

Authors:  Stine E Nielsen; Esben Nielsen; Hanne Olsen Julian; Jens Lindegaard; Klavs Højgaard; Anders Ivarsen; Jesper Hjortdal; Steffen Heegaard
Journal:  Acta Ophthalmol       Date:  2014-05-19       Impact factor: 3.761

6.  Big data and the eyeSmart electronic medical record system - An 8-year experience from a three-tier eye care network in India.

Authors:  Anthony Vipin Das; Priyanka Kammari; Ranganath Vadapalli; Sayan Basu
Journal:  Indian J Ophthalmol       Date:  2020-03       Impact factor: 1.848

Review 7.  Integrated model of primary and secondary eye care for underserved rural areas: the L V Prasad Eye Institute experience.

Authors:  Gullapalli N Rao; Rohit C Khanna; Sashi Mohan Athota; Varda Rajshekar; Padmaja Kumari Rani
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

8.  Outcomes of therapeutic penetrating keratoplasty in 198 eyes with fungal keratitis.

Authors:  Jyothi Mundra; Rohit Dhakal; Ashik Mohamed; Govinda Jha; Joveeta Joseph; Sunita Chaurasia; Somasheila Murthy
Journal:  Indian J Ophthalmol       Date:  2019-10       Impact factor: 1.848

9.  Corneal transplantation and eye banking practices during COVID-19-related lockdown period in India from a network of tertiary eye care centers.

Authors:  Arvind Roy; Sujata Das; Sunita Chaurasia; Merle Fernandes; Somasheila Murthy
Journal:  Indian J Ophthalmol       Date:  2020-11       Impact factor: 1.848

View more
  1 in total

Review 1.  Pythium insidiosum Keratitis: Past, Present, and Future.

Authors:  Bharat Gurnani; Kirandeep Kaur; Shweta Agarwal; Vaitheeswaran G Lalgudi; Nakul S Shekhawat; Anitha Venugopal; Koushik Tripathy; Bhaskar Srinivasan; Geetha Iyer; Joseph Gubert
Journal:  Ophthalmol Ther       Date:  2022-07-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.